✦ LIBER ✦

672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

✍ Scribed by J.-M. Extra; F. Cognetti; S. Chan; D. Maraninchi; R. Snyder; a. Lluch; M. Tubiana-Hulin; D. Grimes; K. Mayne; M. Marty

Book ID: 118620844
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 174 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90703-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trastuzumab (Herceptin®) plus docetaxel

Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

✍ J.M Extra; F Cognetti; D Maranichi; R Snyder; L Mauriac; M Tubiana-Hulin; S Chan 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 348 KB

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

Trastuzumab plus docetaxel with or witho

Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study

✍ A. Wardlev; A. Anton-Torres; X. Pivot; F. Morales-Vasquez; L. Zetina; M. de Fati 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Randomized Phase II Trial of weekly pacl

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

✍ Giampietro Gasparini; Massimo Gion; Luigi Mariani; Paola Papaldo; Diana Crivella 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 222 KB

Phase II Trial of Weekly Docetaxel, Vino

Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

✍ Jeffrey R. Infante; Denise A. Yardley; Howard A. Burris III; F. Anthony Greco; C 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 120 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB